You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser.
Administrator
Staff member
-
cafead Nov 20, 2022 at 01:12: PM
Administrator
Staff member
via
- Editas Medicine has some promising candidates, but plenty of work remains.
- The biotech's prospects look somewhat uncertain, making the stock risky.
article source
<
